Related Experiment Videos
Dyslipidemias and the secondary prevention of coronary heart disease
R S Rosenson1, W A Frauenheim, C C Tangney
1Department of Medicine, Rush University Chicago, Illinois.
Insights
Patients with coronary heart disease and dyslipidemia face higher risks of cardiac events. Lowering low-density lipoprotein cholesterol (LDL-C) through lifestyle changes and medication significantly reduces these risks and slows disease progression.
Area of Science:
- Cardiology
- Metabolic Disorders
- Lipid Metabolism
Background:
- Dyslipidemias significantly increase ischemic cardiac event risk in patients with coronary heart disease (CHD).
- Over 80% of patients with premature CHD have a major dyslipidemia.
- Dyslipidemias involve abnormal levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, high-density lipoproteins (HDL), and lipoprotein(a).
Purpose of the Study:
- To summarize the role of dyslipidemias in CHD and the impact of lipid-lowering therapies.
- To outline current intervention strategies for managing dyslipidemias in CHD patients.
Main Methods:
- Review of clinical trial data on lipid-lowering therapies in CHD patients.
- Analysis of dyslipidemia prevalence and composition in established CHD.
- Evaluation of treatment guidelines for managing hypercholesterolemia and other dyslipidemias.
Main Results:
- Therapy to lower LDL-C levels demonstrably delays coronary stenosis progression and reduces recurrent cardiac events.
- Clinical benefits of LDL-C lowering can be observed within 6 to 12 months.
- Intervention targets LDL-C to 90-100 mg/dl, starting with lifestyle modifications.
Conclusions:
- Aggressive LDL-C reduction is a cornerstone of CHD management.
- Pharmacological intervention is necessary for hypercholesterolemia unresponsive to lifestyle changes.
- Further research is needed to clarify the benefits of treating other dyslipidemias in CHD.
Abstract:
Dyslipidemias in patients with coronary heart disease confer a greater risk of ischemic cardiac events than comparable dyslipidemias in people free of disease. A major dyslipidemia can be diagnosed in more than 80% of patients with established premature coronary heart disease. These dyslipidemias constitute not only elevations of low-density lipoprotein cholesterol (hypercholesterolemia) but also indicate abnormalities in the metabolism of triglyceride-rich lipoproteins, high-density lipoproteins, and lipoprotein(a). Clinical trials have demonstrated that therapy to lower low-density lipoprotein levels can delay angiographic progression of coronary stenoses and reduce recurrent cardiac event rates. These clinical benefits from low-density lipoprotein cholesterol lowering may occur as early as 6 to 12 months after initiation of therapy. Intervention strategies for dyslipidemias are directed toward lowering the low-density lipoprotein cholesterol fraction to 90 to 100 mg/dl. This approach begins with dietary modification, weight loss, smoking cessation, and aerobic exercise. Patients with hypercholesterolemia refractory to nonpharmacologic intervention require lipid-lowering agents. The choice of lipid-lowering medications is influenced by concomitant abnormalities of lipoprotein metabolism, such as hypertriglyceridemia or hypoalphalipoproteinemia. Treatment of primary dyslipidemias other than hypercholesterolemia may be warranted in the presence of other cardiac risk factors; however, a broader spectrum of clinical trial data is needed to support or refute this contention.